Invasive mold infections (IMIs) can complicate intensive myelosuppressive chemotherapy for hematological malignancies, particularly acute leukemia. As allogeneic hematopoietic SCT (HSCT) is often the only curative treatment for the majority of these patients, clinicians often encounter the therapeutic dilemma of balancing further cytotoxic therapy and HSCT with the risk of IMI relapse-related morbidity and death. Although improvements in diagnosis and the introduction of new antifungal agents have improved prognosis for IMIs, the possibility of post-transplant IMI relapse is considerable and historically associated with poor outcomes.
Invasive mold infections (IMIs) can complicate intensive myelosuppressive chemotherapy for hematological malignancies, particularly acute leukemia. As allogeneic hematopoietic SCT (HSCT) is often the only curative treatment for the majority of these patients, clinicians often encounter the therapeutic dilemma of balancing further cytotoxic therapy and HSCT with the risk of IMI relapse-related morbidity and death. Although improvements in diagnosis and the introduction of new antifungal agents have improved prognosis for IMIs, the possibility of post-transplant IMI relapse is considerable and historically associated with poor outcomes. [1] [2] [3] The aim of the present study was to evaluate the IMI relapse rate and associated mortality rate after allogeneic HSCT in a contemporary cohort of patients with hematological malignancies at a tertiary care cancer center. To that end, we retrospectively evaluated all patients at The University of Texas MD Anderson Cancer Center in whom a proven or probable IMI (according to the revised definitions of the European Organization for Research and Treatment of Cancer (EORTC) and Mycoses Study Group (MSG)) developed before HSCT from 1 January 2005 to 31 December 2008. Patients' electronic records were reviewed for their demographic characteristics, underlying hematological malignancies, antifungal treatments, conditioning regimens before HSCT, secondary antifungal prophylaxis, time of IMI relapse, and outcome at 6 and 12 months after HSCT. Treatment response was defined as partial (PR) or complete (CR) or a failure based on the EORTC/MSG consensus criteria. Mortality was attributed to IMI if the patient had clinical, microbiological and/or radiological evidence of active fungal infection at the time of death. An IMI was considered a breakthrough infection if it was caused by an organism different from the one that caused the infection that led to initiation of secondary antifungal prophylaxis, or if it was developed at least within 7 days after initiation of secondary antifungal prophylaxis. The study protocol was approved by the MD Anderson Institutional Review Board.
We identified 29 patients with hematological malignancies and a history of proven or probable IMI before HSCT (Table 1) . Twentysix patients (90%) completed more than 4 weeks of antifungal treatment before undergoing HSCT. Five patients (17%) received surgical management, including sinus debridement and wedge resection. Before HSCT, the majority of patients (80%) were estimated to have CRs (59%) or PRs (21%) to antifungal treatment, with the rest of the patients exhibiting evidence of stable (10%) or progressive (10%) IMI.
All of the patients received secondary antifungal prophylaxis, mainly with second-generation triazoles (93%), at the time of HSCT (Table 2) . Four patients (14%) had breakthrough IMIs after HSCT (three over the 12 months after HSCT). All four of them had antifungal treatment responses before HSCT (two had CRs) and completed more than 4 weeks of antifungal treatment before HSCT. In addition, at the time of breakthrough IMI, all patients had engrafted, and they were not neutropenic. Three of them had relapse of the underlying malignancy at the time of HSCT. Overall, 3 of the 15 patients (20%) with active hematological malignancy at the time of HSCT had a breakthrough IMI compared with only 1 of the 14 patients (7%) with hematological malignancy in remission (P ¼ 0.59). Of note, two of four patients with breakthrough infection experienced development of an IMI different from the one diagnosed before HSCT. One of these two patients had mucormycosis before HSCT, and then had aspergillosis after HSCT while undergoing inappropriate secondary antifungal prophylaxis (voriconazole and caspofungin). The other patient had IMI caused by Curvularia species before HSCT, and then had an IMI caused by Alternaria species after HSCT while receiving voriconazole-based secondary antifungal prophylaxis. In all, 12 (41%) and 14 (48%) patients died within 6 and 12 months after HSCT, respectively. One of these 14 patients (3%) was diagnosed with a breakthrough IMI (fusariosis) on day 70 after HSCT. However, he died of relapsed AML on day 350 after HSCT. Only one patient (7%) underwent an autopsy, which had no findings of IMI.
At present, standardized strategies for secondary antifungal prophylaxis and the optimal time of HSCT in leukemia patients with prior IMIs are lacking. Most of the previous studies regarding secondary prophylaxis in patients with hematological malignancies are retrospective and include small heterogenous patients' populations, with various IMI classifications and different responses to antifungal treatment before HSCT. [2] [3] [4] [5] [6] [7] [8] Nonetheless, studies in which secondary prophylaxis was amphotericin B or first-generation triazoles reported commonly significant rates of relapsed IMIs (29-33%) and associated mortality rates (88%) in patients with hematological malignancies and histories of IMIs before allogeneic HSCT; 2-4 of note, liposomal amphotericin B was also shown to be associated with a high rate of kidney injury (36%). 4 In addition, other investigators described conflicting results about the efficacy of secondary prophylaxis with echinocandins with a wide range of IMI relapse (11-32%). 6, 8 Interestingly, in our study, we observed a relatively low rate of breakthrough IMIs (14%) and no IMI-attributable mortality in a corresponding patient population. Of note, 93% of our patients received a second generation triazole as secondary prophylaxis. Our data are in agreement with those of a recent prospective open-labeled study 9 that also demonstrated a low-relapsed IMI rate after HSCT (7%), as well as previous retrospective studies 5, 7 in the era of secondary prophylaxis with second-generation azoles.
A short interval between initiation of antifungal therapy and HSCT (o4 weeks), lack of prior remission of IMI to antifungal treatment, active underlying hematological malignancy at the time of HSCT, use of myeloablative conditioning regimens, the source of stem cells (mainly BM or cord blood), a prolonged neutropenic phase, CMV infection, and corticosteroids' use for the treatment of GVHD after HSCT have been described as significant risk factors for recurrent IMI. 1, 3, 10 Unfortunately, in our analysis, the small number of cases and recurrent IMIs limited our ability to determine the relative importance of these variables. Notably, the majority of our patients had completed more than 4 weeks of antifungal treatment, and was estimated to have PR or CR before undergoing HSCT. These parameters, in combination with the predominant use of second-generation triazoles as secondary prophylaxis, may explain the low IMI relapse rate, even in high-risk patients with active underlying malignancies receiving unrelated donor transplants. Of interest, two patients had breakthrough IMIs attributed to different molds after HSCT, which demonstrates the potential for the emergence of resistance of fungal pathogens and emphasizes the need for diagnostic vigilance in high-risk patients with prolonged immunosuppression. 7 Our study had several limitations, because of its retrospective nature, the small number of patients, the frequent overlap between continuation of treatment and prophylaxis, and the lack of data regarding therapeutic drug monitoring of triazoles. Nevertheless, our data support the emerging consensus that in the current era of improved diagnostics and expanded antifungal treatment options for IMIs, a history of IMI should not be considered a contraindication to subsequent HSCT in patients with hematological malignancies, especially in those who exhibit clinical responses to initial antifungal treatment, are in hematological remission and receive effective secondary antifungal prophylaxis, based on triazoles.
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